Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Clinical trial NCT07491445 · RECRUITING

Trial details

NCT number: NCT07491445
Sponsor: Revolution Medicines, Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Pancreatic Cancer Pancreatic Cancer Metastatic PDAC PDAC - Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic Pancreatic Adenocarcinoma Pancreatic Adenosquamous Carcinoma

Start date: 2026-03-09
Primary completion: 2028-06-01
Enrollment: 900

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.